Nomura initiates Anthem Biosciences stock with 'Buy', sees strong long-term CRDMO runway
Anthem Biosciences Share Outlook: Nomura initiates coverage on Anthem Biosciences stock with a Buy rating and ₹740 target, citing strong CRDMO growth, high profitability, niche capabilities and a robust medium-term outlook. Key risks and valuation insights inside.
Anthem Biosciences Share Outlook: Nomura initiates coverage on Anthem Biosciences stock with a Buy rating and ₹740 target, citing strong CRDMO growth, high profitability, niche capabilities and a robust medium-term outlook. Key risks and valuation insights inside.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
